Hisafumi Yasuda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hisafumi Yasuda has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
- Akira Shimada
Department of Endocrinology and Diabetes Saitama Medical University Saitama Japan
4 shared publications - Hiroshi Ikegami
Department of Endocrinology, Metabolism and Diabetes, Kindai University Faculty of Medicine, Osaka-sayama, Japan
4 shared publications - Akihisa Imagawa
Department of Internal Medicine (I), Osaka Medical and Pharmaceutical University, 2-7 Daigakumachi, Takatsuki City, Osaka 569-8686, Japan
3 shared publications - Daisuke Chujo
Department of Diabetes, Metabolism and Endocrinology, International University of Health and Welfare Ichikawa General Hospital, 5-1-13 Sugano, Ichikawa, Chiba 272-8513, Japan
3 shared publications - Eiji Kawasaki
Diabetes, Thyroid, and Endocrine Center, Shin-Koga Hospital, Kurume 830-8577, Japan
3 shared publications - Junji Kozawa
Department of Metabolic Medicine, Graduate School of Medicine, Osaka University, Suita, Japan
3 shared publications
Latest Publications
- Open Access
- 19 February 2026
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 10, e87236
Autonomous Motivation Trajectory Following Adoption of a Team-Based Gamification App Among Adults With Diabetes: 1-Year Formative Longitudinal Study
Background: Autonomous motivation, grounded in self-determination theory, is important for sustaining diabetes self-care behaviors. Although mobile health interventions, gamification, and peer support are increasingly used to enhance motivation in diabetes care, evidence on how motivation evolves over time remains limited. Specifically, it is unclear whether motivational change follows a linear pattern or a nonlinear trajectory, such as an initial increase followed by a subsequent decline. Clarifying these temporal patterns is critical for informing the design of adaptive diabetes self-care interventions. Objective: The objective of this study was to characterize the 1-year developmental trajectory of autonomous motivation following the real-world introduction of a commercially available team-based gamification app. Methods: This prospective, single-arm longitudinal study involved adults with diabetes (predominantly type 2) recruited from outpatient clinics in Japan. Participants were instructed to use a team-based gamification app designed to promote desirable habits through peer support and social comparison for at least 7 days. The primary outcome, autonomous motivation, was assessed using the Treatment Self-Regulation Questionnaire–Autonomous Motivation subscale (TSRQ-AM; score range 7-49) at baseline, 6 weeks, 6 months, and 1 year. Secondary measures included hemoglobin A1c (HbA1c), body weight, triglycerides, and psychological scales (eg, Self-Efficacy Scale for Diabetes Self-Care, Summary of Diabetes Self-Care Activities, Problem Areas in Diabetes scale, and World Health Organization–Five Well-Being Index). To analyze the trajectory, we used linear mixed-effects models with random intercepts for participants. The final model included fixed effects for time (as both linear and quadratic terms), age, sex, employment status, family structure, baseline BMI, and baseline HbA1c. Results: Of 32 consenting participants, 29 (90.6%) were included in the primary analysis; clinical data at 1 year were available for 26 (81.3%) participants. In exploratory analyses, mean TSRQ-AM scores increased from baseline (37.4, SD 7.9) to 6 months (39.5, SD 7.4; Cohen d=0.47). Over the 1-year period, body weight decreased significantly (b=−0.39; P=.01), whereas HbA1c (P=.40) and triglycerides (P=.14) showed no significant changes. The TSRQ-AM score showed a significant nonlinear change over time. A model including a quadratic time term fit significantly better than a linear-only model (χ21=4.1; P=.04), with a significant quadratic effect (b=−7.26; P=.045), indicating an inverted U-shaped trajectory peaking at 6 months. Higher baseline BMI was associated with lower TSRQ-AM scores (b=−1.00; P=.001). Conclusions: This formative study provides preliminary evidence of a nonlinear, 1-year trajectory of autonomous motivation following the introduction of a team-based app. The observed curvilinear pattern suggests that autonomous motivation during the intervention may peak at around 6 months, underscoring the importance of adaptive intervention designs to maintain engagement over time. The accompanying reduction in body weight suggests potential physiological relevance that warrants further investigation in controlled studies. Trial Registration: UMIN Clinical Trials Registry UMIN000044874; https://tinyurl.com/59bzb68k
- 19 February 2026
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 10, e87236
Open AccessAutonomous Motivation Trajectory Following Adoption of a Team-Based Gamification App Among Adults With Diabetes: 1-Year Formative Longitudinal Study
Background: Autonomous motivation, grounded in self-determination theory, is important for sustaining diabetes self-care behaviors. Although mobile health interventions, gamification, and peer support are increasingly used to enhance motivation in diabetes care, evidence on how motivation evolves over time remains limited. Specifically, it is unclear whether motivational change follows a linear pattern or a nonlinear trajectory, such as an initial increase followed by a subsequent decline. Clarifying these temporal patterns is critical for informing the design of adaptive diabetes self-care interventions. Objective: The objective of this study was to characterize the 1-year developmental trajectory of autonomous motivation following the real-world introduction of a commercially available team-based gamification app. Methods: This prospective, single-arm longitudinal study involved adults with diabetes (predominantly type 2) recruited from outpatient clinics in Japan. Participants were instructed to use a team-based gamification app designed to promote desirable habits through peer support and social comparison for at least 7 days. The primary outcome, autonomous motivation, was assessed using the Treatment Self-Regulation Questionnaire–Autonomous Motivation subscale (TSRQ-AM; score range 7-49) at baseline, 6 weeks, 6 months, and 1 year. Secondary measures included hemoglobin A1c (HbA1c), body weight, triglycerides, and psychological scales (eg, Self-Efficacy Scale for Diabetes Self-Care, Summary of Diabetes Self-Care Activities, Problem Areas in Diabetes scale, and World Health Organization–Five Well-Being Index). To analyze the trajectory, we used linear mixed-effects models with random intercepts for participants. The final model included fixed effects for time (as both linear and quadratic terms), age, sex, employment status, family structure, baseline BMI, and baseline HbA1c. Results: Of 32 consenting participants, 29 (90.6%) were included in the primary analysis; clinical data at 1 year were available for 26 (81.3%) participants. In exploratory analyses, mean TSRQ-AM scores increased from baseline (37.4, SD 7.9) to 6 months (39.5, SD 7.4; Cohen d=0.47). Over the 1-year period, body weight decreased significantly (b=−0.39; P=.01), whereas HbA1c (P=.40) and triglycerides (P=.14) showed no significant changes. The TSRQ-AM score showed a significant nonlinear change over time. A model including a quadratic time term fit significantly better than a linear-only model (χ21=4.1; P=.04), with a significant quadratic effect (b=−7.26; P=.045), indicating an inverted U-shaped trajectory peaking at 6 months. Higher baseline BMI was associated with lower TSRQ-AM scores (b=−1.00; P=.001). Conclusions: This formative study provides preliminary evidence of a nonlinear, 1-year trajectory of autonomous motivation following the introduction of a team-based app. The observed curvilinear pattern suggests that autonomous motivation during the intervention may peak at around 6 months, underscoring the importance of adaptive intervention designs to maintain engagement over time. The accompanying reduction in body weight suggests potential physiological relevance that warrants further investigation in controlled studies. Trial Registration: UMIN Clinical Trials Registry UMIN000044874; https://tinyurl.com/59bzb68k
- Open Access
- 6 November 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Autonomous Motivation Trajectory Following Adoption of a Team-Based Gamification App Among Adults With Diabetes: 1-Year Formative Longitudinal Study (Preprint)
BACKGROUND Autonomous motivation, grounded in self-determination theory, is important for sustaining diabetes self-care behaviors. Although mobile health interventions, gamification, and peer support are increasingly used to enhance motivation in diabetes care, evidence on how motivation evolves over time remains limited. Specifically, it is unclear whether motivational change follows a linear pattern or a nonlinear trajectory, such as an initial increase followed by a subsequent decline. Clarifying these temporal patterns is critical for informing the design of adaptive diabetes self-care interventions. OBJECTIVE The objective of this study was to characterize the 1-year developmental trajectory of autonomous motivation following the real-world introduction of a commercially available team-based gamification app. METHODS This prospective, single-arm longitudinal study involved adults with diabetes (predominantly type 2) recruited from outpatient clinics in Japan. Participants were instructed to use a team-based gamification app designed to promote desirable habits through peer support and social comparison for at least 7 days. The primary outcome, autonomous motivation, was assessed using the Treatment Self-Regulation Questionnaire–Autonomous Motivation subscale (TSRQ-AM; score range 7-49) at baseline, 6 weeks, 6 months, and 1 year. Secondary measures included hemoglobin A1c (HbA1c), body weight, triglycerides, and psychological scales (eg, Self-Efficacy Scale for Diabetes Self-Care, Summary of Diabetes Self-Care Activities, Problem Areas in Diabetes scale, and World Health Organization–Five Well-Being Index). To analyze the trajectory, we used linear mixed-effects models with random intercepts for participants. The final model included fixed effects for time (as both linear and quadratic terms), age, sex, employment status, family structure, baseline BMI, and baseline HbA1c. RESULTS Of 32 consenting participants, 29 (90.6%) were included in the primary analysis; clinical data at 1 year were available for 26 (81.3%) participants. In exploratory analyses, mean TSRQ-AM scores increased from baseline (37.4, SD 7.9) to 6 months (39.5, SD 7.4; Cohen d=0.47). Over the 1-year period, body weight decreased significantly (b=−0.39; P=.01), whereas HbA1c (P=.40) and triglycerides (P=.14) showed no significant changes. The TSRQ-AM score showed a significant nonlinear change over time. A model including a quadratic time term fit significantly better than a linear-only model (χ21=4.1; P=.04), with a significant quadratic effect (b=−7.26; P=.045), indicating an inverted U-shaped trajectory peaking at 6 months. Higher baseline BMI was associated with lower TSRQ-AM scores (b=−1.00; P=.001). CONCLUSIONS This formative study provides preliminary evidence of a nonlinear, 1-year trajectory of autonomous motivation following the introduction of a team-based app. The observed curvilinear pattern suggests that autonomous motivation during the intervention may peak at around 6 months, underscoring the importance of adaptive intervention designs to maintain engagement over time. The accompanying reduction in body weight suggests potential physiological relevance that warrants further investigation in controlled studies. CLINICALTRIAL UMIN Clinical Trials Registry UMIN000044874; https://tinyurl.com/59bzb68k
- 6 November 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessAutonomous Motivation Trajectory Following Adoption of a Team-Based Gamification App Among Adults With Diabetes: 1-Year Formative Longitudinal Study (Preprint)
BACKGROUND Autonomous motivation, grounded in self-determination theory, is important for sustaining diabetes self-care behaviors. Although mobile health interventions, gamification, and peer support are increasingly used to enhance motivation in diabetes care, evidence on how motivation evolves over time remains limited. Specifically, it is unclear whether motivational change follows a linear pattern or a nonlinear trajectory, such as an initial increase followed by a subsequent decline. Clarifying these temporal patterns is critical for informing the design of adaptive diabetes self-care interventions. OBJECTIVE The objective of this study was to characterize the 1-year developmental trajectory of autonomous motivation following the real-world introduction of a commercially available team-based gamification app. METHODS This prospective, single-arm longitudinal study involved adults with diabetes (predominantly type 2) recruited from outpatient clinics in Japan. Participants were instructed to use a team-based gamification app designed to promote desirable habits through peer support and social comparison for at least 7 days. The primary outcome, autonomous motivation, was assessed using the Treatment Self-Regulation Questionnaire–Autonomous Motivation subscale (TSRQ-AM; score range 7-49) at baseline, 6 weeks, 6 months, and 1 year. Secondary measures included hemoglobin A1c (HbA1c), body weight, triglycerides, and psychological scales (eg, Self-Efficacy Scale for Diabetes Self-Care, Summary of Diabetes Self-Care Activities, Problem Areas in Diabetes scale, and World Health Organization–Five Well-Being Index). To analyze the trajectory, we used linear mixed-effects models with random intercepts for participants. The final model included fixed effects for time (as both linear and quadratic terms), age, sex, employment status, family structure, baseline BMI, and baseline HbA1c. RESULTS Of 32 consenting participants, 29 (90.6%) were included in the primary analysis; clinical data at 1 year were available for 26 (81.3%) participants. In exploratory analyses, mean TSRQ-AM scores increased from baseline (37.4, SD 7.9) to 6 months (39.5, SD 7.4; Cohen d=0.47). Over the 1-year period, body weight decreased significantly (b=−0.39; P=.01), whereas HbA1c (P=.40) and triglycerides (P=.14) showed no significant changes. The TSRQ-AM score showed a significant nonlinear change over time. A model including a quadratic time term fit significantly better than a linear-only model (χ21=4.1; P=.04), with a significant quadratic effect (b=−7.26; P=.045), indicating an inverted U-shaped trajectory peaking at 6 months. Higher baseline BMI was associated with lower TSRQ-AM scores (b=−1.00; P=.001). CONCLUSIONS This formative study provides preliminary evidence of a nonlinear, 1-year trajectory of autonomous motivation following the introduction of a team-based app. The observed curvilinear pattern suggests that autonomous motivation during the intervention may peak at around 6 months, underscoring the importance of adaptive intervention designs to maintain engagement over time. The accompanying reduction in body weight suggests potential physiological relevance that warrants further investigation in controlled studies. CLINICALTRIAL UMIN Clinical Trials Registry UMIN000044874; https://tinyurl.com/59bzb68k
- Open Access
- 15 September 2025
- Published by BMJ in BMJ Open Diabetes Research & Care
- Vol. 13 (5) , e005229
Slowly progressive type 1 diabetes and female sex as associated factors for pancreatic abnormalities on diagnostic imaging indicating precancerous potential
Introduction: This study aimed to identify factors associated with pancreatic abnormal findings on imaging (PAI) suggesting precancerous potential between slowly progressive type 1 diabetes and acute-onset type 1 diabetes. Research design and Methods: The study was designed to identify factors associated with PAI using data from a nationwide cohort, the Japanese Type 1 Diabetes Database. Clinical factors, including sex, age, type of diabetes onset, diabetes duration, body mass index, and human leucocyte antigen genotypes associated with type 1 diabetes, were evaluated. Results: Among 279 patients with type 1 diabetes, 95 patients who had not undergone imaging evaluations, two patients with pancreatic lipomatosis, and 15 patients with missing data were excluded. Finally, a total of 167 patients with type 1 diabetes were analyzed. Among 13 patients who were identified as PAI positive, female sex (92.3% vs 53.2%, p=0.007), slowly progressive type 1 diabetes (69.2% vs 36.4%, p=0.034), and older age were more common compared with PAI-negative cases. The multivariable logistic regression analysis revealed that female sex (OR 13.87; 95% CI 1.6 to 120.1; p=0.017), slowly progressive type 1 diabetes (OR 5.70; 95% CI 1.46 to 22.19; p=0.012), and age (OR 1.05; 95% CI 1.002 to 1.103; p=0.043) were independently associated with PAI positivity. Conclusions: The findings indicate that slowly progressive type 1 diabetes and female sex are closely associated with PAI, along with age. These results suggest the need for increased clinical vigilance for pancreatic pathology in patients with slowly progressive type 1 diabetes.
- 15 September 2025
- Published by BMJ in BMJ Open Diabetes Research & Care
- Vol. 13 (5) , e005229
Open AccessSlowly progressive type 1 diabetes and female sex as associated factors for pancreatic abnormalities on diagnostic imaging indicating precancerous potential
Introduction: This study aimed to identify factors associated with pancreatic abnormal findings on imaging (PAI) suggesting precancerous potential between slowly progressive type 1 diabetes and acute-onset type 1 diabetes. Research design and Methods: The study was designed to identify factors associated with PAI using data from a nationwide cohort, the Japanese Type 1 Diabetes Database. Clinical factors, including sex, age, type of diabetes onset, diabetes duration, body mass index, and human leucocyte antigen genotypes associated with type 1 diabetes, were evaluated. Results: Among 279 patients with type 1 diabetes, 95 patients who had not undergone imaging evaluations, two patients with pancreatic lipomatosis, and 15 patients with missing data were excluded. Finally, a total of 167 patients with type 1 diabetes were analyzed. Among 13 patients who were identified as PAI positive, female sex (92.3% vs 53.2%, p=0.007), slowly progressive type 1 diabetes (69.2% vs 36.4%, p=0.034), and older age were more common compared with PAI-negative cases. The multivariable logistic regression analysis revealed that female sex (OR 13.87; 95% CI 1.6 to 120.1; p=0.017), slowly progressive type 1 diabetes (OR 5.70; 95% CI 1.46 to 22.19; p=0.012), and age (OR 1.05; 95% CI 1.002 to 1.103; p=0.043) were independently associated with PAI positivity. Conclusions: The findings indicate that slowly progressive type 1 diabetes and female sex are closely associated with PAI, along with age. These results suggest the need for increased clinical vigilance for pancreatic pathology in patients with slowly progressive type 1 diabetes.
- 13 June 2025
- Published by American Diabetes Association in Diabetes Care
- Vol. 48 (8) , 1438-1445
Rapid and Slow Progressors Toward β-Cell Depletion and Their Predictors in Type 1 Diabetes: Prospective Longitudinal Study in Japanese Type 1 Diabetes (TIDE-J)
OBJECTIVE: This study aimed to investigate the progression of β-cell dysfunction and its predictors in Japanese patients with type 1 diabetes, using data from the nationwide, multicenter, prospective longitudinal Japanese Type 1 Diabetes Database Study (TIDE-J). RESEARCH DESIGN AND METHODS: TIDE-J enrolled 314 Japanese individuals with type 1 diabetes, including 165 with acute-onset, 105 with slowly progressive, and 44 with fulminant type 1 diabetes. Clinical data, including C-peptide levels, glycemic control, and autoantibody status, were collected annually for up to 14 years. HLA genotypes were analyzed at study entry. The time to insulin depletion was analyzed using survival curves and Cox proportional hazards models to determine predictive factors. RESULTS: The rate of undetectable C-peptide varied significantly among subtypes. At 5 years after onset, 43.1% (n = 55) of patients with acute-onset, 9.1% (n = 7) with slowly progressive, and 93.2% (n = 38) with fulminant type 1 diabetes reached undetectable C-peptide. Even within acute-onset type 1 diabetes, a marked interindividual variation was observed in the progression toward β-cell depletion. HLA genotypes influenced progression rates as follows: DRB1*04:05-DQB1*04:01/DRB1*04:05-DQB1*04:01 (DR4/DR4) carriers exhibited slower β-cell depletion, whereas DR4/DRB1*08:02-DQB1*03:02 (i.e., DR4/DR8) and DR4/DRB1*09:01-DQB1*03:03 (i.e., DR4/DR9) were associated with a rapid progression. For slowly progressive type 1 diabetes, low BMI, GAD antibody positivity, and absence of the DRB1*15:01-DQB1*06:02 or DRB1*15:02-DQB1*06:01 (i.e., DR2) haplotype were predictive of progression to insulin dependence. CONCLUSIONS: This study elucidates the heterogeneity in β-cell dysfunction among Japanese individuals with type 1 diabetes and identifies genetic and clinical predictors of disease progression. These findings provide insights for individualized management strategies and future therapeutic interventions.
- 13 June 2025
- Published by American Diabetes Association in Diabetes Care
- Vol. 48 (8) , 1438-1445
Rapid and Slow Progressors Toward β-Cell Depletion and Their Predictors in Type 1 Diabetes: Prospective Longitudinal Study in Japanese Type 1 Diabetes (TIDE-J)
OBJECTIVE: This study aimed to investigate the progression of β-cell dysfunction and its predictors in Japanese patients with type 1 diabetes, using data from the nationwide, multicenter, prospective longitudinal Japanese Type 1 Diabetes Database Study (TIDE-J). RESEARCH DESIGN AND METHODS: TIDE-J enrolled 314 Japanese individuals with type 1 diabetes, including 165 with acute-onset, 105 with slowly progressive, and 44 with fulminant type 1 diabetes. Clinical data, including C-peptide levels, glycemic control, and autoantibody status, were collected annually for up to 14 years. HLA genotypes were analyzed at study entry. The time to insulin depletion was analyzed using survival curves and Cox proportional hazards models to determine predictive factors. RESULTS: The rate of undetectable C-peptide varied significantly among subtypes. At 5 years after onset, 43.1% (n = 55) of patients with acute-onset, 9.1% (n = 7) with slowly progressive, and 93.2% (n = 38) with fulminant type 1 diabetes reached undetectable C-peptide. Even within acute-onset type 1 diabetes, a marked interindividual variation was observed in the progression toward β-cell depletion. HLA genotypes influenced progression rates as follows: DRB1*04:05-DQB1*04:01/DRB1*04:05-DQB1*04:01 (DR4/DR4) carriers exhibited slower β-cell depletion, whereas DR4/DRB1*08:02-DQB1*03:02 (i.e., DR4/DR8) and DR4/DRB1*09:01-DQB1*03:03 (i.e., DR4/DR9) were associated with a rapid progression. For slowly progressive type 1 diabetes, low BMI, GAD antibody positivity, and absence of the DRB1*15:01-DQB1*06:02 or DRB1*15:02-DQB1*06:01 (i.e., DR2) haplotype were predictive of progression to insulin dependence. CONCLUSIONS: This study elucidates the heterogeneity in β-cell dysfunction among Japanese individuals with type 1 diabetes and identifies genetic and clinical predictors of disease progression. These findings provide insights for individualized management strategies and future therapeutic interventions.
- Open Access
- 30 September 2022
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 14 (1) , 58-66
Comparing the clinical significance and antigen specificity of insulinoma‐associated antigen‐2 autoantibodies between radioimmunoassay and enzyme‐linked immunosorbent assay in Japanese patients with type 1 diabetes
Aims/Introduction: This study aimed to investigate the clinical significance and antigen specificity of autoantibodies to insulinoma‐associated antigen‐2 (IA‐2A) by radioimmunoassay (RIA; IA‐2A‐RIA) and enzyme‐linked immunosorbent assay (ELISA; IA‐2A‐ELISA) in Japanese patients with type 1 diabetes.Materials and Methods: A total of 338 type 1 diabetic patients were enrolled, including 38 fulminant type 1 diabetes, 168 acute‐onset type 1 diabetes and 137 slowly‐progressive type 1 diabetes (SPIDDM). The concordance, correlation of autoantibody titer, and the relationship between IA‐2A and progression to the insulin‐deficient state were examined. Also, competitive assay was used to examine the antigen specificity.Results: The prevalence of IA‐2A‐ELISA was 4–5% lower than that of IA‐2A‐RIA in both the acute‐onset type 1 diabetes and SPIDDM, but the diagnostic sensitivities of both subtypes, when measured in combination with glutamic acid decarboxylase autoantibody, were comparable. The diagnosis of type 1 diabetes using either the RIA or ELISA methods showed substantial agreement with the exponential correlation of autoantibody titers detected by RIA and ELISA. Among the SPIDDM patients, the fasting C‐peptide for IA‐2A‐positive cases by ELISA, but not the RIA method, was significantly lower than in the negative cases (P < 0.05). Furthermore, IA‐2A‐ELISA proved superior to the RIA method in predicting the progression to insulin deficiency in SPIDDM. Competitive analysis showed that even sera with discrepant results by RIA and ELISA have IA‐2‐specific autoantibodies.Conclusion: These results suggest that IA‐2A‐ELISA is a reliable marker not only for the diagnosis of type 1 diabetes, but also for the prediction of future insulin dependency; that is, detection of IA‐2A‐ELISA helps identify a subtype of SPIDDM patients who would likely progress onto insulin‐deficient state.
- 30 September 2022
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 14 (1) , 58-66
Open AccessComparing the clinical significance and antigen specificity of insulinoma‐associated antigen‐2 autoantibodies between radioimmunoassay and enzyme‐linked immunosorbent assay in Japanese patients with type 1 diabetes
Aims/Introduction: This study aimed to investigate the clinical significance and antigen specificity of autoantibodies to insulinoma‐associated antigen‐2 (IA‐2A) by radioimmunoassay (RIA; IA‐2A‐RIA) and enzyme‐linked immunosorbent assay (ELISA; IA‐2A‐ELISA) in Japanese patients with type 1 diabetes.Materials and Methods: A total of 338 type 1 diabetic patients were enrolled, including 38 fulminant type 1 diabetes, 168 acute‐onset type 1 diabetes and 137 slowly‐progressive type 1 diabetes (SPIDDM). The concordance, correlation of autoantibody titer, and the relationship between IA‐2A and progression to the insulin‐deficient state were examined. Also, competitive assay was used to examine the antigen specificity.Results: The prevalence of IA‐2A‐ELISA was 4–5% lower than that of IA‐2A‐RIA in both the acute‐onset type 1 diabetes and SPIDDM, but the diagnostic sensitivities of both subtypes, when measured in combination with glutamic acid decarboxylase autoantibody, were comparable. The diagnosis of type 1 diabetes using either the RIA or ELISA methods showed substantial agreement with the exponential correlation of autoantibody titers detected by RIA and ELISA. Among the SPIDDM patients, the fasting C‐peptide for IA‐2A‐positive cases by ELISA, but not the RIA method, was significantly lower than in the negative cases (P < 0.05). Furthermore, IA‐2A‐ELISA proved superior to the RIA method in predicting the progression to insulin deficiency in SPIDDM. Competitive analysis showed that even sera with discrepant results by RIA and ELISA have IA‐2‐specific autoantibodies.Conclusion: These results suggest that IA‐2A‐ELISA is a reliable marker not only for the diagnosis of type 1 diabetes, but also for the prediction of future insulin dependency; that is, detection of IA‐2A‐ELISA helps identify a subtype of SPIDDM patients who would likely progress onto insulin‐deficient state.
- 14 December 2018
- Published by American Diabetes Association in Diabetes
- Vol. 68 (3) , 665-675
Genome-Wide Association Study Confirming a Strong Effect of HLA and Identifying Variants inCSAD/lnc-ITGB7-1on Chromosome 12q13.13 Associated With Susceptibility to Fulminant Type 1 Diabetes
The first genome-wide association study of fulminant type 1 diabetes mellitus was performed in Japanese individuals. As previously reported using a candidate gene approach, a strong association was observed with multiple SNPs in the HLA region, and the strongest association was observed with rs9268853 in the class II DR region (P=1.56 x 10-23, odds ratio [OR] 3.18). In addition, rs11170445 in CSAD/lnc-ITGB7-1 on chromosome 12q13.13 showed an association at a genome-wide significance level (P=7.58 x 10-9, OR 1.96). Fine mapping of the region revealed that rs3782151 in CSAD/lnc-ITGB7-1 showed the lowest P value (P=4.60 x 10-9, OR 1.97 [95% CI 1.57-2.48]). The risk allele of rs3782151 is a cis-expression quantitative trait locus (eQTL) for ITGB7 that significantly increases the expression of this gene. CSAD/lnc-ITGB7-1 was found to be strongly associated with susceptibility to fulminant, but not classical, autoimmune type 1 diabetes, implicating this locus in the distinct phenotype of fulminant type 1 diabetes.
- 14 December 2018
- Published by American Diabetes Association in Diabetes
- Vol. 68 (3) , 665-675
Genome-Wide Association Study Confirming a Strong Effect of HLA and Identifying Variants inCSAD/lnc-ITGB7-1on Chromosome 12q13.13 Associated With Susceptibility to Fulminant Type 1 Diabetes
The first genome-wide association study of fulminant type 1 diabetes mellitus was performed in Japanese individuals. As previously reported using a candidate gene approach, a strong association was observed with multiple SNPs in the HLA region, and the strongest association was observed with rs9268853 in the class II DR region (P=1.56 x 10-23, odds ratio [OR] 3.18). In addition, rs11170445 in CSAD/lnc-ITGB7-1 on chromosome 12q13.13 showed an association at a genome-wide significance level (P=7.58 x 10-9, OR 1.96). Fine mapping of the region revealed that rs3782151 in CSAD/lnc-ITGB7-1 showed the lowest P value (P=4.60 x 10-9, OR 1.97 [95% CI 1.57-2.48]). The risk allele of rs3782151 is a cis-expression quantitative trait locus (eQTL) for ITGB7 that significantly increases the expression of this gene. CSAD/lnc-ITGB7-1 was found to be strongly associated with susceptibility to fulminant, but not classical, autoimmune type 1 diabetes, implicating this locus in the distinct phenotype of fulminant type 1 diabetes.
- 1 June 2011
- Published by Elsevier in Clinical Immunology
- Vol. 139 (3) , 336-349
IL-10-conditioned dendritic cells prevent autoimmune diabetes in NOD and humanized HLA-DQ8/RIP-B7.1 mice
- 1 June 2011
- Published by Elsevier in Clinical Immunology
- Vol. 139 (3) , 336-349
IL-10-conditioned dendritic cells prevent autoimmune diabetes in NOD and humanized HLA-DQ8/RIP-B7.1 mice
- 1 June 2008
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 80 (3) , 352-359
Prevention of recurrent but not spontaneous autoimmune diabetes by transplanted NOD islets adenovirally transduced with immunomodulating molecules
- 1 June 2008
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 80 (3) , 352-359
Prevention of recurrent but not spontaneous autoimmune diabetes by transplanted NOD islets adenovirally transduced with immunomodulating molecules